摘要
目的分析甘精胰岛素在2型糖尿病患者中应用效果及其安全性。方法研究对象来自浙江省温岭市第四人民医院内分泌科2011年1月～2013年1月收治的120例2型糖尿病患者，随机其分为对照组和实验组各60例。对照组采用低精蛋白重组人胰岛素治疗，实验组采用甘精胰岛素治疗，比较两组患者临床疗效和安全性。结果14d后，两组患者空腹血糖、餐后2h血糖、空腹C肽、糖化血红蛋白均优于治疗前，但是，两组比较差异无统计学意义（P〉0．05）。实验组患者血糖达标平均时间和血糖达标平均费用均明显少于对照组（P〈0．05）。结论甘精胰岛素和低精蛋白重组人胰岛素控制空腹血糖、餐后2h血糖、空腹C肽和糖化血红蛋白效果相当。从经济学角度，可优先考虑甘精胰岛素。
Objective To investigate the clinical efficacy and safety of type 2 diabetes patients treated by insulin glargine in order to provide a reference for optimizing type 2 diabetes treatment plan. Methods One hundred and twen- ty type 2 diabetes patients who were in the endocrinology department of the fourth people＇s hospital in wenling city of zhejiang province from January 2011 to January 2013 were chosen as the research objects, they were randomly divided into the control group with 60 cases and the experimental group with 60 cases. The patients in the control group were given low protamine recombinant human insulin treatment, while the patients in the experimental group were given in- sulin glargine treatment.The clinical efficacy and safety were compared. Results After 14 days treatment, with the fast- ing plasma glucose, postprandial 2 hours blood glucose, fasting C peptide and glycosylated hemoglobin of two groups patients were better than the before treatment （P〈0.05）, there was no statistically significant difference between two groups（P〉0.05）. The blood sugar at an average time and average blood glucose at target costs in the experimental group patients were significantly less than that of patients in the control group （P〈0.05）. Conclusion The clinical efficacy of type 2 diabetes patients by insulin glargine and low protamine recombinant human insulin is quite.It can control fasting plasma glucose, postprandial 2 hours blood glucose, fasting C peptide and glycosylated hemoglobin, however, from an economic point of view,we should give priority to insulin glargine.
出处
《中国现代医生》
2014年第5期47-49,共3页
China Modern Doctor
基金
浙江省卫生厅医药卫生计划项目(2011KYB010)
